ATE452640T1 - Mittel für erkrankungen assoziert mit knochensubstanzverlust - Google Patents

Mittel für erkrankungen assoziert mit knochensubstanzverlust

Info

Publication number
ATE452640T1
ATE452640T1 AT00977860T AT00977860T ATE452640T1 AT E452640 T1 ATE452640 T1 AT E452640T1 AT 00977860 T AT00977860 T AT 00977860T AT 00977860 T AT00977860 T AT 00977860T AT E452640 T1 ATE452640 T1 AT E452640T1
Authority
AT
Austria
Prior art keywords
diseases associated
remedies
bone loss
agonist
decrease
Prior art date
Application number
AT00977860T
Other languages
English (en)
Inventor
Tanaka Masaharu
Oida Hiroji
Original Assignee
Ono Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co filed Critical Ono Pharmaceutical Co
Application granted granted Critical
Publication of ATE452640T1 publication Critical patent/ATE452640T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT00977860T 1999-11-24 2000-11-22 Mittel für erkrankungen assoziert mit knochensubstanzverlust ATE452640T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP33349099 1999-11-24
JP2000056534 2000-03-01
JP2000119188 2000-04-20
PCT/JP2000/008235 WO2001037877A1 (en) 1999-11-24 2000-11-22 Remedies for diseases in association with decrease in bone mass

Publications (1)

Publication Number Publication Date
ATE452640T1 true ATE452640T1 (de) 2010-01-15

Family

ID=27340604

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00977860T ATE452640T1 (de) 1999-11-24 2000-11-22 Mittel für erkrankungen assoziert mit knochensubstanzverlust

Country Status (16)

Country Link
US (1) US6891062B2 (de)
EP (1) EP1232757B1 (de)
JP (1) JP3705360B2 (de)
KR (1) KR100654653B1 (de)
CN (1) CN1262309C (de)
AT (1) ATE452640T1 (de)
AU (1) AU783939B2 (de)
CA (1) CA2391526A1 (de)
DE (1) DE60043587D1 (de)
ES (1) ES2337333T3 (de)
HU (1) HUP0203590A3 (de)
MX (1) MXPA02005173A (de)
NO (1) NO20022442L (de)
NZ (1) NZ519101A (de)
TW (1) TWI247606B (de)
WO (1) WO2001037877A1 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04000454A (es) * 2001-07-16 2004-03-18 Hoffmann La Roche Derivados de 2-pirrolidona como agonistas de prostanoides.
NZ530885A (en) 2001-07-23 2007-09-28 Ono Pharmaceutical Co Remedies for diseases with bone mass loss having EP4 agonist as the active ingredient
WO2003041717A1 (fr) * 2001-11-12 2003-05-22 Ono Pharmaceutical Co., Ltd. Preparation pelliculaire persistante pour administration localisee contenant un derive de prostaglandine
EP1506220A1 (de) * 2002-05-23 2005-02-16 Theratechnologies Inc. Antagonistische peptide für den prostaglandin-e2-rezeptor-subtyp ep4
EP1878741A3 (de) * 2002-05-23 2008-02-20 Theratechnologies Inc. Antagonistische Peptide aus dem Prostaglandin-E2-Rezeptor vom Untertyp EP4
JPWO2006075690A1 (ja) * 2005-01-14 2008-06-12 小野薬品工業株式会社 安定な医薬組成物
US7531533B2 (en) 2005-01-27 2009-05-12 Asahi Kasei Pharma Corporation 6-Membered heterocyclic compound and use thereof
JPWO2006118173A1 (ja) 2005-04-28 2008-12-18 小野薬品工業株式会社 経皮吸収製剤
US7998500B2 (en) 2005-08-04 2011-08-16 Vertical Pharmaceuticals, Inc. Nutritional supplement for women
US8202546B2 (en) 2005-08-04 2012-06-19 Vertical Pharmaceuticals, Inc. Nutritional supplement for use under physiologically stressful conditions
US8263137B2 (en) 2005-08-04 2012-09-11 Vertical Pharmaceuticals, Inc. Nutritional supplement for women
US7901710B2 (en) 2005-08-04 2011-03-08 Vertical Pharmaceuticals, Inc. Nutritional supplement for use under physiologically stressful conditions
JP5247675B2 (ja) 2006-03-24 2013-07-24 チルドレンズ メディカル センター コーポレーション 造血性幹細胞の増殖を調節する方法
JP5426389B2 (ja) * 2006-10-20 2014-02-26 チルドレンズ メディカル センター コーポレーション 組織の再生を亢進するための方法
EP2085088A4 (de) 2006-10-26 2012-08-29 Ono Pharmaceutical Co Klebende zubereitung
AU2008246579A1 (en) 2007-05-08 2008-11-13 National University Corporation, Hamamatsu University School Of Medicine Cytotoxic T cell activator comprising EP4 agonist
US20110206781A1 (en) * 2008-05-28 2011-08-25 Zon Leonard I Method to modulate hematopoietic stem cell growth
WO2010096264A2 (en) 2009-02-03 2010-08-26 Children's Medical Center Corporation Methods for enhancing hematopoietic stem/progenitor cell engraftment
US9051548B2 (en) 2009-02-03 2015-06-09 Children's Medical Center Corporation Methods for enhancing hematopoietic stem/progenitor cell engraftment
EP2454227B1 (de) 2009-07-13 2020-08-19 Patheon API Services Inc. Prostanoid-synthese
ES2682255T3 (es) 2011-12-02 2018-09-19 Fate Therapeutics, Inc. Métodos mejorados de tratamiento de isquemia
CA2857640C (en) 2011-12-02 2021-11-16 Fate Therapeutics, Inc. Enhanced stem cell composition
EP3175852B1 (de) 2012-07-19 2019-03-06 Cayman Chemical Company, Incorporated Difluorolactamzusammensetzungen für ep4-vermittelte osteoverwandte erkrankungen und leiden
US9676712B2 (en) 2013-03-15 2017-06-13 Cayman Chemical Company, Inc. Lactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions
US10851412B2 (en) 2013-03-15 2020-12-01 Fate Therapeutics, Inc. Cell potency assay for therapeutic potential
EP3235817B1 (de) 2013-03-15 2018-12-12 Cayman Chemical Company, Incorporated Lactamverbindungen als ep4-rezeptorselektive agonisten zur verwendung bei der behandlung von ep4-vermittelten erkrankungen und zuständen
AU2014290512A1 (en) 2013-07-19 2015-11-12 Cayman Chemical Company, Inc. Methods, systems, and compositions for promoting bone growth
JP6488472B2 (ja) 2013-09-30 2019-03-27 パテオン エーピーアイ サービシーズ インコーポレイテッドＰａｔｈｅｏｎ Ａｐｉ Ｓｅｒｖｉｃｅｓ Ｉｎｃ． メタセシスを用いるプロスタグランジンおよびプロスタグランジン中間体の新規合成経路
EA037327B1 (ru) 2015-09-22 2021-03-12 Грейбуг Вижн, Инк. Соединения и композиции для лечения глазных расстройств

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0951282T3 (da) * 1996-12-20 2008-07-14 Pfizer Forebyggelse og behandling af skeletlidelse med EP2-receptorsubtype-selektive prostaglandin E2-agonister
JPH10265454A (ja) 1997-01-27 1998-10-06 Ono Pharmaceut Co Ltd ３，７−ジチアプロスタン酸誘導体、それらの製造方法およびそれらを有効成分として含有する薬剤
US6124314A (en) * 1997-10-10 2000-09-26 Pfizer Inc. Osteoporosis compounds
GB2330307A (en) * 1998-02-07 1999-04-21 Glaxo Group Ltd EP4 Receptor antagonists as bone resorption inhibitors
US6043275A (en) * 1998-04-16 2000-03-28 Ono Pharmaceutical Co., Ltd. 3,7-dithiaprostanoic acid derivative
TWI249520B (en) 1998-07-15 2006-02-21 Ono Pharmaceutical Co 5-Thia-omega-substituted phenyl prostaglandin E derivatives, method for producing the same and medicines containing the same as the active ingredient
US6586468B1 (en) * 1998-09-14 2003-07-01 Ono Pharmaceutical Co., Ltd. ω-substituted phenyl-prostaglandin E derivatives and drugs containing the same as the active ingredient
CA2346031A1 (en) * 1998-10-15 2000-04-20 Merck & Co., Inc. Methods for stimulating bone formation

Also Published As

Publication number Publication date
DE60043587D1 (de) 2010-02-04
WO2001037877A1 (en) 2001-05-31
HUP0203590A3 (en) 2006-07-28
TWI247606B (en) 2006-01-21
EP1232757A4 (de) 2004-06-16
NO20022442D0 (no) 2002-05-23
MXPA02005173A (es) 2004-02-26
US20040209848A1 (en) 2004-10-21
ES2337333T3 (es) 2010-04-23
US6891062B2 (en) 2005-05-10
NO20022442L (no) 2002-07-24
HUP0203590A2 (hu) 2003-03-28
JP3705360B2 (ja) 2005-10-12
AU1548501A (en) 2001-06-04
EP1232757B1 (de) 2009-12-23
CN1262309C (zh) 2006-07-05
KR20020059774A (ko) 2002-07-13
CN1424918A (zh) 2003-06-18
EP1232757A1 (de) 2002-08-21
CA2391526A1 (en) 2001-05-31
AU783939B2 (en) 2006-01-05
NZ519101A (en) 2004-04-30
KR100654653B1 (ko) 2006-12-07

Similar Documents

Publication Publication Date Title
ATE452640T1 (de) Mittel für erkrankungen assoziert mit knochensubstanzverlust
DE69732170D1 (de) Formulierung mit verzögerter Freisetzung enthaltend Kollagen und Glykosaminoglykan
AU2002223684A1 (en) Combination comprising an agent decreasing vegf activity and an agent decreasing egf activity
BRPI9908182B8 (pt) composições de proteína de matriz para cura de feridas
ATE241334T1 (de) Mittel zur förderung des haarwachstums
BR9917038A (pt) Composto, composição farmacêutica, método de modulação da atividade receptora de quimocinas, método de tratamento ou prevenção de doenças inflamatórias, método de tratamento ou prevenção de asma e método de tratamento ou prevenção de disfunções inflamatórias
WO2003000343A3 (en) Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
BRPI0412526A (pt) composto, uso de um composto, composição farmacêutica, formulação em aerossol farmacêutica, e, método para o tratamento de um paciente humano ou animal com uma condição anti-inflamatória e/ou alérgica
WO2003051294A3 (en) Mitocidal compositions and methods
WO2001028491A3 (en) Method and composition for the treatment of dermatologic diseases
BR0114799A (pt) Compostos de ácido cianofenoxi carboxìlico e composições para liberar agentes ativos
ATE336255T1 (de) Hyaluronsäure-ester zur behandlung von normotrophischen hautnarben
FR2856294B1 (fr) Utilisation cosmetique d'une composition comprenant au moins une oxazoline, a titre de principe actif, comme amincissant et/ou pour prevenir et/ou traiter la cellulite
AU1865100A (en) Hyaluronate lyase used for promoting penetration in topical agents
ATE473749T1 (de) Verwendung von rhamnolipiden zur wundheilung, behandlung und vorbeugung einer zahnfleischerkrankung und periodontaler regeneration
ATE417617T1 (de) Mittel zur steurung der expression von il-12
DE60035429D1 (de) Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen
EP1262197A3 (de) Kombinationstherapie zur Behandlung von Schlafstörungen, Schlaflosigkeit inbegriffen
ATE390124T1 (de) Behandlung von mastitis mit einer kombination aus prednisolon und cephalosporin
CA2340734A1 (en) Optically active pyridyl-4h-1,2,4-oxadiazine derivative and its use in the treatment of vascular diseases
ATE289204T1 (de) Arzneimittel zur vorbeugung / behandlung / inhibierung des fortschritts für einfache oder preproliferative retinopathie
BR0015781A (pt) Composição farmacêutica para tratamento de doenças associadas à diminuição de massa óssea
WO2002060533A3 (de) Betamimetika enthaltende arzneimittelkompositionen mit geringere n nebenwirkungen
SE0000303D0 (sv) Novel compounds
BR0116554A (pt) Composto, composição farmacêutica para o tratamento da angina ou hipertensão, processo, processo para o tratamento ou prevenção da angina ou hipertensão, composição do ingrediente farmaceuticamente ativo e composição farmacêutica para o tratamento ou prevenção da angina ou hipertensão

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties